Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Head and Neck Squamous Cell Carcinoma|Melanoma Excluding Uveal Melanoma|Non-small Cell Lung Cancer, Squamous or Non-squamous|Urothelial Carcinoma|Renal Cell Carcinoma, Clear Cell|Castration-resistant Prostate Cancer|Ovarian Cancer, Epithelial|TNBC - Triple-Negative Breast Cancer|Colorectal Cancer
Interventions: BIOLOGICAL: XmAb®808|BIOLOGICAL: Keytruda® (pembrolizumab)
Sponsor: Xencor, Inc.